Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines
NCT05028257Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Viral Vector Vaccines, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05028257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028257.